Premium
Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family
Author(s) -
Chiang HueiHsin,
Rosvall Lina,
Brohede Jesper,
Axelman Karin,
Björk Behnosh F.,
Nennesmo Inger,
Robins Tiina,
Graff Caroline
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.09.001
Subject(s) - frontotemporal dementia , frameshift mutation , mutation , genetics , biology , frontotemporal lobar degeneration , dementia , family history , phenotype , gene , disease , medicine
Background Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by cognitive impairment, language dysfunction, and/or changes in personality. Recently it has been shown that progranulin ( GRN ) mutations can cause FTD as well as other neurodegenerative phenotypes. Methods DNA from 30 family members, of whom seven were diagnosed with FTD, in the Karolinska family was available for GRN sequencing. Fibroblast cell mRNA from one affected family member and six control individuals was available for relative quantitative real‐time polymerase chain reaction to investigate the effect of the mutation. Furthermore, the cDNA of an affected individual was sequenced. Results Clinical and neuropathologic findings of a previously undescribed family branch are presented. A frameshift mutation in GRN (g.102delC) was detected in all affected family members and absent in four unaffected family members older than 70 years. Real‐time polymerase chain reaction data showed an ∼50% reduction of GRN fibroblast mRNA in an affected individual. The mutated mRNA transcripts were undetectable by cDNA sequencing. Conclusions Segregation and RNA analyses showed that the g.102delC mutation, previously reported, causes FTD in the Karolinska family. Our findings add further support to the significance of GRN in FTD etiology and the presence of modifying genes, which emphasize the need for further studies into the mechanisms of clinical heterogeneity. However, the results already call for attention to the complexity of predictive genetic testing of GRN mutations.